Avobenzone: Effective UVA Filter, Unstable and Absorbed

Last updated September 21, 2026

Carries no SPF rating, because SPF measures only the rays it does not cover.

2/5 protection rating
UVA only

Avobenzone (butyl methoxydibenzoylmethane) is the most common UVA filter in US chemical sunscreens. While effective at absorbing UVA radiation, it suffers from significant photostability issues and demonstrates concerning levels of systemic absorption.

Chemical Properties and UV Protection

Avobenzone, marketed as Parsol 1789, is a dibenzoylmethane derivative that absorbs UVA radiation in the 320-400 nm range. It's the only chemical UVA filter approved in the US at concentrations up to 3%, making it essential for broad-spectrum protection in chemical sunscreens.

UV Absorption Spectrum

Avobenzone provides peak absorption at 357 nm, covering the UVA I range (340-400 nm) that penetrates deep into the dermis. This long-wave UVA protection is critical for preventing photoaging, DNA damage, and melanoma. However, avobenzone provides no UVB protection, requiring combination with other filters.

Photostability Challenges

Rapid Photodegradation

Without stabilizers, avobenzone degrades by 50% after just 1 hour of UV exposure, significantly reducing the sunscreen's effectiveness. This photodegradation occurs through keto-enol tautomerization when exposed to UV light, breaking down the molecule and eliminating its protective capacity.

To address instability, manufacturers combine avobenzone with photostabilizers:

Systemic Absorption Research

FDA Absorption Studies (2019-2020)

FDA clinical trials found avobenzone is absorbed well past the agency's 0.5 ng/mL testing threshold — the level below which some additional nonclinical safety studies may be waived. Peak plasma concentrations reached 4.3 ng/mL (8.6x the threshold) in the 2019 pilot trial and 7.1 ng/mL (14x) from a lotion in the larger 2020 trial, and remained elevated for days after use stopped.

Key findings from systemic absorption studies:

Safety Concerns

Endocrine Disruption Potential

While less studied than oxybenzone, emerging research suggests avobenzone may have endocrine-disrupting properties. Studies have found it can affect androgen and progesterone receptors, though at lower potency than other chemical filters.

Allergic Reactions

Avobenzone is associated with allergic and photoallergic contact dermatitis. The degradation products formed during photodegradation may be more allergenic than the parent compound, particularly in individuals with sensitive skin.

Environmental Impact

Avobenzone has been detected in surface waters and wastewater treatment plants. While not currently banned like oxybenzone, studies show it can bioaccumulate in aquatic organisms and may contribute to coral bleaching at high concentrations.

Regulatory Status

United States: Approved at up to 3% concentration. FDA has requested additional safety data but has not reached a final determination on GRASE (Generally Recognized As Safe and Effective) status.

European Union: Approved at up to 5% concentration. No current restrictions, though under review for potential endocrine effects.

Other regions: Widely approved globally, though some countries are reviewing safety data in light of absorption studies.

Australia: Permitted under TGA regulation (as butyl methoxydibenzoylmethane). The TGA's 2025 safety review found a margin of safety above 100 and considers it low-risk at permitted levels.

Canada: Permitted under Health Canada's Primary Sunscreen Monograph; avobenzone is the standard UVA filter in Canadian chemical sunscreens, as in the US.

Formulation Considerations

Due to its instability and absorption concerns, avobenzone presents formulation challenges:

  1. Stabilization requirements: Must be combined with photostabilizers, increasing formula complexity
  2. Oil solubility: Requires oil phase or solubilizers in water-based formulas
  3. Incompatibilities: Cannot be formulated with mineral sunscreens (degrades faster)
  4. Concentration limits: 3% maximum limits UVA protection achievable

What the Absorption Trials Actually Tested

The FDA's maximal-use trials are the strongest evidence on this page, and they describe their sunscreens by formulation type only — lotion, aerosol spray, non-aerosol spray, pump spray. Neither paper names a commercial product, so no brand can be attached to these numbers.

The 2020 trial (48 participants, four formulations)

Participants applied 2 mg/cm² of one sunscreen to 75% of body surface area, 13 times over four days, with 34 blood samples drawn across 21 days. Avobenzone's geometric mean maximum plasma concentration was 7.1 ng/mL from the lotion (14 times the FDA's 0.5 ng/mL level), 3.5 ng/mL from the aerosol spray, 3.5 ng/mL from the non-aerosol spray and 3.3 ng/mL from the pump spray. A single application on day 1 was already enough to pass 0.5 ng/mL in every formulation (1.6, 1.2, 1.0 and 0.7 ng/mL respectively). Avobenzone stayed above 0.5 ng/mL through day 7 in 95% of participants (42 of 44). The lotion, not the spray, gave the highest levels.

Reference: Matta MK, Florian J, Zusterzeel R, et al. Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2020;323(3):256-267. doi:10.1001/jama.2019.20747.

The 2019 pilot (24 participants, four formulations)

The earlier pilot used the same maximal-use design over seven days of sampling and reported avobenzone maximum plasma concentrations of 4.3 ng/mL for the lotion (8.6 times the threshold), 4.0 and 3.4 ng/mL for two sprays, and 1.8 ng/mL for a cream.

Reference: Matta MK, Zusterzeel R, Pilli NR, et al. Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2019;321(21):2082-2091. doi:10.1001/jama.2019.5586.

Four further product claims once sat in this section — two photostability comparisons, one in vitro endocrine test and one combination-filter study, each naming a commercial sunscreen. None of their citations resolves to a real paper in PubMed, so all four were removed in September 2026 rather than left with a figure whose source cannot be named.

Alternatives and Recommendations

For those concerned about avobenzone's absorption and stability issues, alternatives include:

Given the systemic absorption data and photostability challenges, individuals may want to minimize avobenzone exposure, particularly with daily use products. When using avobenzone-containing sunscreens, reapplication every 2 hours is essential due to photodegradation.

Recommended: La Roche-Posay Anthelios Mineral Sunscreen SPF 50 — an avobenzone-free mineral alternative — photostable zinc oxide and titanium dioxide

Our Verdict: 2/5

Avobenzone is essential for UVA protection in US chemical sunscreens but suffers from severe photostability issues and concerning systemic absorption levels that exceed FDA safety thresholds.

Pros

  • Provides critical UVA I protection (340-400 nm range)
  • Only chemical UVA filter approved in the US
  • Effective at 3% concentration when properly stabilized
  • Allows for lightweight, transparent formulations

Cons

  • Degrades by 50% after 1 hour of UV exposure without stabilizers
  • Absorbed into blood at 14x the FDA's 0.5 ng/mL level from a lotion under maximal use
  • Requires additional chemicals like octocrylene for stabilization
  • Associated with allergic reactions and hormone disruption concerns

Related

← Back to Conventional Sunscreens